In line with previous studies on CRC, mutations observed in TP53, KRAS, and APC were mostly such postulated deleterious variants, and had a similar frequency in both responders and non-responders (Figure 2A and Supplementary Table S3). Here, TP53 is linked to colorectal carcinoma.